CompletedPhase 2NCT04461587
Examination of Pirfenidone (Esbriet®) Therapy in Coal Workers' Pneumoconiosis With Pulmonary Fibrosis
Studying Pneumoconiosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Pulmonary Research of Abingdon, LLC
- Principal Investigator
- Emory Robinette, MDPulmonary Research of Abingdon, LLC
- Intervention
- Pirfenidone(drug)
- Enrollment
- 50 target
- Eligibility
- 40-79 years · All sexes
- Timeline
- 2020 – 2022
Study locations (1)
- Pulmonary Research of Abingdon, LLC, Abingdon, Virginia, United States
Collaborators
Genentech, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04461587 on ClinicalTrials.govOther trials for Pneumoconiosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06563674Acceptance-based Healthy Lifestyles Program for Patients With PneumoconiosisChinese University of Hong Kong
- RECRUITINGPHASE3NCT05288179Efficacy and Safety of Pirfenidone Capsules in the Treatment of PneumoconiosisBeijing Continent Pharmaceutical Co, Ltd.
- RECRUITINGNCT07077382Pneumoconiosis and Dust Exposure China CohortChina-Japan Friendship Hospital